We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SDHC:NYSESmith Douglas Homes Corp. Analysis

Data as of 2026-06-22 - not real-time

$13.75

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Smith Douglas Homes trades at $13.75, comfortably above its 20‑day ($12.85) and 50‑day ($13.10) moving averages but still below the long‑term 200‑day average ($16.28), signaling a short‑term bounce within a broader bearish backdrop. The RSI sits at 57.8, indicating neutral momentum, while the MACD line sits above its signal with a positive histogram, suggesting modest bullish pressure. However, the stock exhibits a steep 30‑day volatility of roughly 55 % and a beta above 1.3, underscoring heightened price swings relative to the market.
Fundamentally, SDHC reports an 8 % revenue decline, thin profit margins (0.9 % net), and a debt‑to‑equity ratio over 16×, raising solvency concerns despite a respectable ROE of 12.8 %. The forward PE of 22.2 is higher than the trailing 14.5, reflecting earnings pressure, while the DCF fair‑value estimate of $35.5 suggests the current price is modestly overvalued by about 2 %. The stock carries no dividend, the industry PE average sits near 32×, and the Fear & Greed Index shows “Extreme Greed,” hinting at potential market complacency.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price hovering above support at $11.13
  • positive MACD histogram indicating short‑term momentum
  • high 30‑day volatility may cause erratic moves

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • 8 % year‑over‑year revenue contraction
  • debt‑to‑equity exceeding 16× raises leverage risk
  • valuation near fair with DCF $35.5 versus market $13.75

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • cyclical real‑estate development exposure to interest‑rate cycles
  • absence of dividend eliminates income component
  • persistent earnings pressure and high leverage limit upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth-8.10%
Profit Margin0.90%
P/E Ratio14.5
ROE12.75%
ROA6.37%
Debt/Equity16.15
P/B Ratio1.5
Op. Cash Flow$3.9M
Free Cash Flow$25.7M
Industry P/E32.3

Technical Analysis

TrendBearish
RSI57.8
Support$11.13
Resistance$14.48
MA 20$12.85
MA 50$13.10
MA 200$16.28
MACDBullish
VolumeStable
Fear & Greed Index91.46

Valuation

Fair Value$35.51
Target Price$13.50
Upside/Downside-1.82%
GradeFair
TypeValue

Risk Assessment

Beta1.43
Volatility54.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.